


# 19<sup>th</sup> — hybrid — WCIRD

World Congress Insulin Resistance  
**DIABETES & CARDIOVASCULAR DISEASE**  
**LIVE IN-PERSON ONLINE**  
**December 2–4, 2021**

EARN  
CME  
ABIM-MOC  
CREDIT  
24.00



Administered by Metabolic Institute of America

Exploring New Frontiers In Metabolism – Tomorrow's Clinical Science Today

JOINTLY PROVIDED



ADMINISTERED BY:



@wcirdc #WCIRD2021



Welcome.

It is my pleasure to invite you to the 19th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC): Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

We are excited to announce that the 19th Annual WCIRDC returns live in person to the Hilton Universal City, Los Angeles. Based on last year’s incredible success we continue to offer virtual participation- Live Online and On-Demand for 3 months, to accommodate our attendees from across the globe.

Since its inception, the congress has become the premier global meeting dedicated to metabolism- obesity, diabetes, lipids, HTN, CKD, CVD, HF, and NAFLD. This is the only conference of its size that incorporates both clinical and basic science. It offers an exclusive opportunity for professionals, researchers, and other clinicians to collaborate on emerging scientific and management strategies. The WCIRDC faculty consists of distinguished global experts who link research to clinical practice in a bench-to-bedside-to-bench approach that is unique to this state-of-the-art program.

During the 19th WCIRDC, we will honor Drs. Christos Mantzoros and Samuel Klein, the recipients of the 2020 and 2021 Gerald Reaven Distinguished Leader in Insulin Resistance Award. This year’s conference will cover a wide range of topics including the most up-to-date CV outcome trials, research in - and management recommendations for- Obesity, Diabetes insulin resistance, COVID-19, dyslipidemia, NAFLD & NASH, ASCVD, heart failure, CKD, CardioRenalMetabolism in youth, hormones and atherosclerosis and much more.

Highlights of the conference will be: a special session- first time ever: Multispecialty — Management of Diabetes, Cardiorenal & Metabolic Diseases — Practice Recommendations 2022; Diabetes — Past, Present & Future; CKD, HF and ASCVD in patients with & without Diabetes; a Joint session with the Journal Metabolism; A Glimpse in the Future — What’s in the Pipeline? Has the Beta Cell Been Forgotten?

Live in-person attendees will be able to participate in clinical workshops, meet the expert sessions and have an opportunity to personally interact and meet, in an intimate setting, the world’s top professionals, experts, and most esteemed leaders in their respective fields.

The 19th WCIRDC congress will feature a robust Poster Hall, Oral Abstract Presentations, an attractive Exhibit Hall, and Industry Supported non-CME programs that will feature important new scientific concepts with some the world’s best-known educators of their fields.

I look forward to you joining this exciting conference on December 2–4, 2021, in Los Angeles.

Best regards,



Yehuda Handelsman, MD  
Chair & Program Director

## Scientific Organizing Committee - International Committee for Insulin Resistance - ICIR

**Yehuda Handelsman, MD Chair**  
Tarzana, CA

**Richard N. Bergman, PhD**  
Los Angeles, CA

**Zachary T. Bloomgarden, MD**  
New York, NY

**Matthew J. Budoff, MD**  
Los Angeles, CA

**Sonia Caprio, MD**  
New Haven, CT

**Robert J. Chilton, DO**  
San Antonio, TX

**Kenneth Cusi, MD**  
Gainesville, FL

**Jaime A. Davidson, MD**  
Dallas, TX

**Ralph A. DeFronzo, MD**  
San Antonio, TX

**Daniel Einhorn, MD**  
La Jolla, CA

**Vivian A. Fonseca, MD**  
New Orleans, LA

**W. Timothy Garvey, MD**  
Birmingham, AL

**Peter J. Grant, MD**  
Leeds, United Kingdom

**Jennifer Green, MD**  
Durham, North Carolina

**George Grunberger, MD**  
Bloomfield Hills, MI

**Chris K. Guerin, MD**  
Oceanside, CA

**Paul S. Jellinger, MD**  
Hollywood, FL

**Samuel Klein, MD**  
St. Louis, MO

**Mikhail N. Kosiborod, MD**  
Kansas City, MO

**Ronald M. Krauss, MD**  
Berkeley, CA

**Norman Lopor, MD**  
Los Angeles, CA

**Derek LeRoith, MD, PhD**  
New York, NY

**Philip Levy, MD**  
Phoenix, AZ

**Christos Mantzoros, MD, PhD**  
Boston, MA

**Nikolaus Marx, MD**  
Aachen, Germany

**Tracey L. McLaughlin, MD**  
Stanford, CA

**Christian W. Mende, MD**  
La Jolla, CA

**Jorge Plutzky, MD**  
Boston, MA

**Richard Pratley, MD**  
Orlando, FL

**Arun J. Sanyal, MD**  
Richmond, VA

**Philipp E. Scherer, PhD**  
Dallas, TX

**Alan R. Sinaiko, MD**  
Minneapolis, MN

**Bart Staels, PhD**  
Lille, France

**Pam R. Taub, MD**  
San Diego, CA

**Muthiah Vaduganathan, MD, MPH**  
Boston, MA

**Matthew R. Weir, MD**  
Baltimore, MD

**Paul Zimmet, AO, PhD**  
Melbourne, Australia



## PROGRAM DESCRIPTION

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 19th year, is a unique and exciting multidisciplinary CME conference. The Congress has become the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

WCIRDC 2021 will return to Live in Person meeting at the Hilton Universal City Hotel in Los Angeles, on December 2-4, 2021. The conference will also have a virtual component- Streaming Live online followed by 90 days On Demand.

In this CME meeting participants can earn up to 24 CME & ABIM-MOC credits.

WCIRDC is the only meeting of its size combining basic and clinical science. For nearly two decades it has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to bedside- to-bench. “I heard it first at the Congress” is a frequent remark from the audience. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty. In an intimate setting, for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, obesity, CVD, the Congress’ focus has expanded to cover the kidney, liver, brain, bone, cancer, and more. The congress addresses

dyslipidemia, atherosclerosis, hypertension, hypercoagulation, inflammation, and energy metabolism. It provides the newest clinical updates on pharmaceutical interventions such as GLP1ra, SGLT2i’s, PCSK9i’s, MRA and EPA to name a few. The goal is to understand the state-of-the-art pathophysiology, new medical interventions, and to develop appropriate comprehensive clinical management strategies.

To make basic and clinical research topics relevant to clinical medicine, following each session there will be live Q&A and a discussion on implications to clinical practice. To promote more interaction with faculty and provide further insights, each day will end with one hour of live panel, providing summary of the day, commentary, and open for Q&A.

The Congress attracts state-of-the-art abstracts attracting, young up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be published in *Metabolism*, a peer-reviewed journal and also available for 90 days on demand.

The congress is featured by many media outlets with proceedings featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News, Practical Cardiology, HCP Live, and more, while articles are being published in peer-reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, Diabetes and its complications and others.

## PROGRAM OBJECTIVES

The program is designed to evaluate the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CVD, HF, CKD, and related cardiometabolic conditions; focusing on basic science such as insulin resistance, fat cells, inflammation, and on clinical practice; understanding the comprehensive management cardiorenalmetabolic conditions.

Upon completion of this meeting, participants should be able to:

- Discuss COVID-19 in diabetes and Obesity.
- Describe the relationship between diabetes, obesity, and heart failure
- Discuss T1D obesity and CVD
- Discuss the role of the beta cells in diabetes
- Discuss the role of fat cells in the development of cardiometabolic conditions
- Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD, and strokes
- Provide the traditional comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia.
- Highlight the paradigm shift in management focusing on preventing the next event of ASCVD, HF and CKD
- Discuss the role of GLP1ra in the management of diabetes, obesity, and prevention of ASCVD.
- Evaluate SGLT2 inhibitors role in reducing cardiovascular morbidity & mortality in patients with and without T2D and at risk for or established CVD
- Address SGLT2i role in managing patients with CKD and HFrEF & HFpEF
- Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
- Discuss fatty liver disease and its relationship to diabetes and CVD
- Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
- Examine the impact of Coagulation in diabetes in prevention of CVD and CVA
- Technology in monitoring and reducing DM & ASCVD
- Address the multispecialty practice recommendations to managing patients with cardiorenalmetabolic diseases

## TARGET AUDIENCE

This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/GYN, researchers, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, CVD, CKD, HF, and associated conditions, as well as the effect of these conditions on health and society.

7:00 am Pre-Registration  
**7:00 am – 8:00 am EXHIBIT HALL OPEN**  
 8:00 am – 8:15 am Welcome & Introduction | Pre-CME Questions

<b>SESSION 1</b>		<b>Has the Beta Cell Been Forgotten?</b>	
Chair: Ralph DeFronzo, MD			
8:15 am	Beta Cell Failure and T2DM: Human Studies	Muhammad Abdul-Ghani, MD, PhD	
8:30 am	Role of Glucotoxicity and Lipotoxicity in Beta Cell Failure	John Leahy, MD	
8:45 am	Beta Cell Insulin Resistance Contributes to Impaired Insulin Secretion	Rohit Kulkarni, MD, PhD	
9:00 am	Gene Mutations Play a Dominant Role in Beta Cell Failure in T2DM	Steven Kahn, MD	
9:15 am	Antidiabetic Agents and Prevention of Beta Cell Failure: Fact & Fiction	Ralph DeFronzo, MD	
9:30 am – 9:50 am	Panel Discussion and Q&A		

<b>SESSION 2</b>		<b>COVID-19 in CardioRenalMetabolism</b>	
Chairs: Chris Guerin, MD • Christian W. Mende, MD			
9:50 am	Cardiovascular Complications of COVID: Challenges and Insights	Michael E. Farkouh, MD	
10:05 am	Obesity and COVID-19 – What is the Link?	Tracey L. McLaughlin, MD	
10:20 am	Managing Inflammation in COVID-19 Patients Focus on Colchicine	Norman E. Lepor, MD	
10:35 am – 10:50 am	Panel Discussion and Q&A		

**10:50 – 11:20 am REFRESHMENT BREAK**

11:20 am – 12:10 pm	Concurrent Sessions	MEET THE EXPERTS	(In-Person Only)
	Daniel Einhorn, MD	Cortisol & Metabolism	Sierra C/D
	Ralph DeFronzo, MD	Everything Insulin Resistance	Club Room
	Matthew Budoff, MD	ASCVD Diagnosis Management	Hiro Room
	Yehuda Handelsman, MD	DM & the Heart A Paradigm Shift	Salon 6AB

**12:15 pm – 1:15 pm LUNCH BREAK**

<b>12:20 pm - 1:05 pm</b>	<b>Lunch Session</b>	<b>Non-CME</b>	<b>Product Theater Hall</b>
	Jardiance® (empagliflozin) tablets: A Review of the Latest Data		Norman Lepor, MD
	Supported by: Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC		



<b>SESSION 3</b>		<b>The Liver: NAFLD &amp; NASH</b>	
Chairs: Jennifer Green, MD • Daniel Einhorn, MD			
1:15 pm	Diagnosis and Treatment of Patients with NAFLD/NASH – The Future	Mazen Noureddin, MD	
1:35 pm	The Liver and the Heart	Laurence Sperling, MD	
1:55 pm – 2:10 pm	Panel Discussion and Q&A		

## THURSDAY, DECEMBER 2, 2021 (cont.)

### SESSION 4 CardioRenalMetabolism in Youth

Chairs: Alan R. Sinaiko, MD • Sonia Caprio, MD

2:10 pm	Value of Early Lipid-Lowering Interventions to Prevent Later Life Cardiovascular Disease	Andrew Moran, MD, MPH
2:25 pm	Co-existence of Prediabetes and Non-Alcoholic Fatty Liver Disease in Pediatric Obesity	Sonia Caprio, MD
2:40 pm	Long-term complications in youth-onset type 2 diabetes: the TODAY study	Phil Zeitler, MD, PhD
2:55 pm – 3:15 pm	Panel Discussion and Q&A	

### 3:15 pm – 3:45 pm REFRESHMENT BREAK

### SESSION 5 Diabetes – Special Populations

Chairs: Zachary Bloomgarden, MD • Tracey L. McLaughlin, MD

3:45 pm	LADA: Epidemiology similarities & differences from T2D/T1D – Impact on Comorbidities	Richard E. Pratley, MD
4:05 pm	C-peptide Levels and CVD Outcomes in the VADT	Peter Reaven, MD
4:25 pm – 4:35 pm	Panel Discussion and Q&A	

### SESSION 6 Dyslipidemia & ASCVD

Chairs: Paul S. Jellinger, MD • Matthew J. Budoff, MD

4:35 pm	Beyond LDL-C: The Role of Dyslipidemia in ASCVD	Ron M. Krauss, MD
4:55 pm	Novel Agents and Combination Therapy in Management of Dyslipidemia	Erin D. Michos, MD
5:15 pm – 5:30 pm	Panel Discussion and Q&A	

### 5:30 pm – 6:30 pm DAY 1 SUMMARY SESSION & POST-CME QUESTIONS

Sonia Caprio, MD • Ralph A. DeFronzo, MD • Jennifer Green, MD • Yehuda Handelsman, MD • Ronald M. Krauss, MD • Tracey L. McLaughlin, MD

### 6:30 pm – 7:30 pm WELCOME AND POSTER RECEPTION

7:30 pm – 8:30 pm

#### Dinner Session

An Overview of the FreeStyle Libre 2 System

Supported by: Abbott

#### Non-CME

#### Product Theater Hall

George Grunberger, MD



## FRIDAY, DECEMBER 3, 2021

7:00 am – 8:00 am EXHIBIT HALL OPEN | Continental Breakfast

8:00 am – 8:10 am Pre-CME Questions

### SESSION 7 Metabolism & WCIRDC – Joint Session

Chair: Michael A. Hill, PhD • Yehuda Handelsman, MD

8:10 am	Insulin Action / Insulin Resistance / Diabetes and the Heart	Dale Abel, MD, PhD
8:25 am	Cardiovascular Actions and Therapeutic Potential of Novel Anti-Diabetic Agents	Michael A. Hill, PhD
8:40 am	Drug Development for Cardiometabolic Disorders - Focusing on the Patient	Theodoros Kelesidis, MD, PhD
8:55 am – 9:10 am	Panel Discussion and Q&A	

## FRIDAY, DECEMBER 3, 2021 (cont.)

### SESSION 8 Hormones, Cytokine, & Insulin – Role in Morbidities

Chairs: Richard N. Bergman, PhD • Samuel Klein, MD

9:10 am	Insulin Action and Insulin Resistance in the Kidney	Gerald I. Shulman, MD, PhD
9:25 am	FGF1 and Insulin Control Adipose Lipolysis by Convergent Pathways	Ronald M. Evans, PhD
9:40 am	Adiponectin & Leptin Roles in Cardiometabolic Control, Diabetes, Aging and Mortality	Philipp E. Scherer, PhD
9:55 am – 10:15 am	Panel Discussion and Q&A	

### 10:15 am – 10:45 am REFRESHMENT BREAK

### SESSION 9 Pumps, CGM, Risk Engine and Hypoglycemia

Chairs: Richard E. Pratley, MD • W. Timothy Garvey, MD

10:45 am	BRAVO risk Engine – Simulating Trials and Evaluating Cost	Vivian A. Fonseca, MD
11:00 am	Clinical Guidelines 2021 - CGM and Insulin Pump Therapy	George Grunberger, MD
11:15 am	Hypoglycemia Contemporary approach to management	Guillermo Umpierrez, MD
11:30 am – 11:45 am	Panel Discussion and Q&A	

### SESSION 10 A Glimpse in the Future - What's in the Pipeline? (Non-CME)

Chairs: Ralph DeFronzo, MD • Tracey L. McLaughlin, MD

11:45 am	Zealand	David Kendall, MD
12:00 pm	Boehringer Ingelheim	Mohamed Eid, MD, MPH, MHA
12:15 pm	Corcept	Joe Belanoff, MD
12:30 pm	Regeneron	Sergio Fazio, MD, PhD
12:45 pm – 1:00 pm	Panel Discussion and Q&A	

### 1:00 pm – 2:00 pm LUNCH BREAK

**1:10 pm – 1:55 pm Lunch Session Non-CME**  
Primary Hypercortisolism: What are We Missing and Why Does it Matter?  
Supported by: Corcept Therapeutics

**Product Theater Hall**  
Daniel Einhorn, MD



### SESSION 11 Multispecialty – Management of Diabetes, Cardio Renal & Metabolic Diseases – Practice Recommendations

Chair: Yehuda Handelsman, MD

2:00 pm	Matthew Budoff, MD • Daniel Einhorn, MD • Vivian Fonseca, MD • Jennifer Green, MD • George Grunberger, MD • Christian Mende, MD • Erin D. Michos, MD	
3:00 pm – 3:30 pm	Panel Discussion and Q&A	

### 3:30 pm – 4:00 pm REFRESHMENT BREAK

### SESSION 12 The Heart, Metabolism and CVOT

Chairs: Peter J. Grant, MD • Norman E. Lepor, MD

4:00 pm	Aortic Stenosis and Metabolic Diseases	Robert J. Chilton, DO
4:15 pm	Testosterone Treatment Impact on Atherosclerosis in Men	Matthew J. Budoff, MD
4:30 pm	Impact of Hormones on Cardiometabolic Health	Pam R. Taub, MD
4:45 pm	Update on CVOTs	Mikhail N. Kosiborod, MD
5:10 pm – 5:30 pm	Panel Discussion and Q&A	

## FRIDAY, DECEMBER 3, 2021 (cont.)

### 5:30 pm – 6:30 pm DAY 2 SUMMARY SESSION & POST-CME QUESTIONS

Ralph DeFronzo, MD • Yehuda Handelsman, MD • Samuel Klein, MD  
Mikhail N. Kosiborod, MD • Norman E. Lepor, MD • Richard E. Pratley, MD

6:30 pm – 7:30 pm

**Dinner Session**

**Non-CME**

**Product Theater Hall**

Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C  
Supported by: **Esperion Therapeutics**

Norman Lepor, MD



### 7:30 pm – 9:00 pm ABSTRACT ORAL PRESENTATION

**Sierra C/D**

**Cheese & Wine**

Zachary Bloomgarden, MD, Chair

Abstract Committee: Daniel Einhorn, MD • George Grunberger, MD • Philip Levy, MD

Abstracts are published in **Metabolism** Editor-in-Chief: **Christos S. Mantzoros, MD, PhD**



## SATURDAY, DECEMBER 4, 2021

7:00 am – 8:00 am

Continental Breakfast

7:00 am – 7:45 am

**Morning Session**

**Non-CME**

**Product Theater Hall**

Clinical Utility of Glycated Albumin & Validation Studies as an  
Intermediate Glycemic Control Marker  
Supported by: **Asahi Kasei Pharma Corporation**

Cyrus Desouza, MBBS



8:00 am – 8:05 am

Abstract Oral Winner Presentation

8:05 am – 8:15 am

Pre-CME Questions

### SESSION 13 Diabetes – Past, Present & Future

Chairs: George Grunberger, MD • Vivian A. Fonseca, MD

8:15 am

Insulin - 100 years of Progress

Jay S. Skyler, MD

8:30 am

The Importance of Long Term Management of Hyperglycemia

Peter J. Grant, MD

8:45 am

Early Combination Therapy in DM - Impact on Comorbidities

Jennifer Green, MD

9:00 am

Reversing Type 2 Diabetes from Day One

Julio Rosenstock, MD

9:15 am – 9:35 am

Panel Discussion and Q&A

### SESSION 14 Obesity 2021 – A Paradigm Shift

Chairs: Ronald M. Krauss, MD • Matthew R. Weir, MD

9:35 am

A New Era in Obesity Medicine: Treat-to-Target

W. Timothy Garvey, MD

9:50 am

What's the Best Weight Loss Diet?

Donna H. Ryan, MD

10:05 am

Key Concepts in Treating Obesity as a Disease: A Focus on Pharmacological Interventions

Ania Jastreboff, MD, PhD

10:20 am - 10:35 am

**REFRESHMENT BREAK**

# SATURDAY, DECEMBER 4, 2021(cont.)

## GERALD REAVEN DISTINGUISHED LEADER IN INSULIN RESISTANCE – 2021 AWARD

10:35 am 2021 Award Presentation “Gerald Reaven Distinguished Leader in Insulin Resistance”

10:40 am Why Does Obesity Cause Type 2 Diabetes

Samuel Klein, MD



11:10 am – 11:30 am Session 14 Panel Discussion and Q&A

### 11:30 am – 12:30 pm LUNCH BREAK

11:40 am – 12:25 pm **Lunch Session** **Non-CME** **Product Theater Hall**

The Role of the Gut in Type 2 Diabetes: Going Beyond Incretins

Supported by: Fractyl Health



Geltrude Mingrone, MD, PhD



Randy Seeley, PhD

### SESSION 15 Glucose Metabolism and Diabetes

Chairs: Philipp E. Scherer, PhD • Richard N. Bergman, PhD

12:30 pm Insulin Resistance Impact on Insulin Clearance and Metabolic Demand Effect on Glucose Tolerance

Ralph DeFronzo, MD

12:45 pm Statin Associated with Increased Insulin Resistance & Diabetes

Joshua W. Knowles, MD

1:00 pm – 1:10 pm Panel Discussion and Q&A

### SESSION 16 CKD, HF and ASCVD in Diabetes & Without

Chairs: Pam R. Taub, MD • Peter J. Grant, MD

1:10 pm The Role of (Micro) Albuminuria in Predicting HF, ASCVD and CKD

Richard E. Pratley, MD

1:25 pm The Prevention of ASCVD in Patients with Diabetes

Ildiko Lingvay, MD

1:40 pm Update in HF Management – How Should/Would the Guidelines Look?

Mikhail N. Kosiborod, MD

### 1:55 pm – 2:10 pm REFRESHMENT BREAK

2:10 pm Heart Failure today: A new epidemic or a co-morbidity

Mark Kearney, MD

2:25 pm The Contemporary Approach to MRA, Aldosterone in the Kidney and the Heart

Christian W. Mende, MD

2:40 pm Treatment of Diabetic Nephropathy: what does the future hold?

Robert D. Toto, MD

2:55 pm – 3:15 pm Panel Discussion and Q&A

### 3:15 pm – 4:10 pm DAY 3 SUMMARY SESSION & POST-CME QUESTIONS

Richard N. Bergman, PhD • W. Timothy Garvey, MD • Peter J. Grant, MD

George Grunberger, MD • Yehuda Handelsman, MD • Pam R. Taub, MD

### 4:15 pm – 5:00 pm Concurrent Sessions CLINICAL WORKSHOPS (In-Person Only)

Management of DM

Sierra Ballroom C/D

Yehuda Handelsman, MD

All You Wanted to Know about CGM

Sierra Ballroom B

George Grunberger, MD

Lipids

Club Room

Paul Jellinger, MD • Paul Rosenblit, MD





# FACULTY 2021



## **Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE**

Medical Director & Principal Investigator  
The Metabolic Institute of America  
Chair & Program Director  
World Congress on Insulin Resistance,  
Diabetes & Cardiovascular Disease (WCIRDC)  
/ Heart in Diabetes (HID)  
Chair & Founder  
International Committee for Insulin Resistance  
Tarzana, California



## **Muhammad Abdul-Ghani, MD, PhD**

Professor of Medicine, Division of Diabetes  
University of Texas Health Science  
Center at San Antonio  
San Antonio, TX



## **Dale Abel, MD, PhD**

Professor & Head  
Internal Medicine  
University of Iowa Carver College of Medicine  
Iowa City, Iowa



## **Joseph K. Belanoff, MD**

Chief Executive Officer, President and Director  
Concept Therapeutics



## **Richard N. Bergman, PhD**

Alfred Jay Firestein Chair in Diabetes  
Research Professor  
Department of Biomedical Sciences  
Cedars-Sinai Director  
Sports Spectacular Diabetes and Obesity  
Wellness and Research Center (SSDOWRC)  
Professor-in-Residence,  
Department of Medicine, UCLA  
Los Angeles, California



## **Zachary T. Bloomgarden, MD, MACE**

Clinical Professor Department of Medicine  
Icahn School of Medicine at Mount Sinai  
Editor, The Journal of Diabetes  
New York, New York



## **Matthew J. Budoff, MD FACC, FAHA**

Professor of Medicine  
David Geffen School of Medicine at UCLA  
Endowed Chair of Preventive Cardiology  
Program Director, Director of Cardiac CT  
Lundquist Institute  
Harbor-UCLA Medical Center  
Division of Cardiology  
Los Angeles, California



## **Sonia Caprio, MD**

Professor of Pediatric Endocrinology  
Yale University School of Medicine  
New Haven, Connecticut



## **Robert J. Chilton, DO, FACP, FACC, FAHA, MACOI, FASCAI**

Professor of Medicine  
Department of Medicine  
Division of Cardiology  
The University of Texas Health Science Center  
San Antonio, Texas



## **Ralph A. DeFronzo, MD**

Professor of Medicine Chief  
Diabetes Division  
University of Texas Health Science  
Center at San Antonio  
San Antonio, Texas



## **Mohamed A. Eid, MD MPH, MHA**

Head of Clinical Development & Medical Affairs  
Cardio-Renal-Metabolism &  
Respiratory Medicine  
Boehringer Ingelheim Pharmaceuticals Inc.  
Ridgefield, Connecticut



## **Daniel Einhorn, MD, FACP, FACE**

Chief, Diabetes and Endocrine Associates  
Medical Director  
Scripps Whittier Diabetes Institute  
Clinical Professor, UCSD School of Medicine  
La Jolla, California



## **Ronald M. Evans, PhD**

Professor and Director  
Gene Expression Laboratory  
March of Dimes Chair in Molecular and  
Developmental Biology  
La Jolla, California



## **Michael E. Farkouh, MD, MSc, FRCP, FACC, FAHA**

Peter Munk Chair in Multinational Clinical Trials  
Director, Heart & Stroke Richard Lewar  
Centre of Excellence  
Vice-Chair Research & Professor of Medicine  
Department of Medicine  
University of Toronto  
Toronto, Ontario, Canada



## **Sergio Fazio, MD, PhD**

Chair, Scientific Council - CV/Metabolic  
Regeneron Pharmaceuticals  
New York, New York



## **Vivian A. Fonseca, MD, FRCP**

Professor of Medicine and Pharmacology  
Assistant Dean for Clinical Research  
Tullis Tulane Alumni Chair in Diabetes  
Chief, Section of Endocrinology  
Tulane University Health Sciences Center  
New Orleans, Louisiana



## **W. Timothy Garvey, MD**

Butterworth Professor  
Department of Nutrition Sciences  
University of Alabama at Birmingham  
Director, UAB Diabetes Research Center  
Birmingham, Alabama



## **Peter J. Grant, MD FRCP, FMedSci**

Professor of Medicine  
Honorary Consultant Physician  
University of Leeds  
Leeds Teaching Hospitals NHS Trust  
Division of Cardiovascular & Diabetes Research  
LIGHT Laboratories  
Leeds, United Kingdom



## **Jennifer Green, MD**

Professor of Medicine  
Duke University Medical Center  
Division of Endocrinology  
Duke Clinical Research Institute  
Durham, North Carolina

**FACULTY 2021**



**George Grunberger, MD**  
**FACP, MACE**

Chairman, Grunberger Diabetes Institute  
Clinical Professor, Internal Medicine and  
Molecular Medicine & Genetics  
Wayne State University School of Medicine  
Professor, Internal Medicine  
Oakland University William Beaumont  
School of Medicine  
Visiting Professor, Internal Medicine  
First Faculty of Medicine  
Charles University, Prague, Czech Republic  
Bloomfield Hills, Michigan



**Chris K. Guerin, MD**

Chief, Division of Endocrinology and  
Metabolism  
Tri-City Medical Center at Oceanside, California  
Founder-Advanced Metabolic Care and  
Research  
Voluntary Assistant Clinical Professor  
University of California at San Diego  
Chair Past President's Committee for CACE  
and Board of Directors  
San Diego, California



**Michael A. Hill, PhD**

Interim Director, Dalton Cardiovascular  
Research Center  
Professor, Department of Medical  
Pharmacology and Physiology,  
School of Medicine  
University of Missouri Columbia, Missouri



**Ania Jastreboff, MD, PhD**

Associate Professor  
Director, Weight Management &  
Obesity Prevention  
Medical Director, Yale Stress Center  
New Haven, Connecticut



**Paul S. Jellinger, MD, MACE**

Professor of Clinical Medicine  
Voluntary Faculty University of Miami, Miller  
School of Medicine  
The Center for Diabetes & Endocrine Care  
Past President, AACE & ACE  
Hollywood, Florida



**Steven E. Kahn, MD**

Division of Metabolism  
Endocrinology and Nutrition  
Department of Medicine  
VA Puget Sound Health Care System  
University of Washington  
Seattle, Washington



**Mark Kearney, MD**  
**MBChB, MRCP**

British Heart Foundation Professor of  
Cardiovascular and Diabetes Research  
Leeds Institute of Cardiovascular  
& Metabolic Medicine  
Dean of the School of Medicine  
University of Leeds  
Leeds, United Kingdom



**Theodoros Kelesidis, MD, PhD**

Associate Professor  
Department of Medicine  
Division of Infectious Diseases  
David Geffen School of Medicine at UCLA  
Encino, California



**David Kendall, MD**

Sr. Global Medical Advisor  
Zealand Pharma  
Westlake Village, California



**Samuel Klein, MD**

Director, Center for Human Nutrition  
Chief Scientific Officer, Sansum Diabetes  
Research Institute  
Washington University School of Medicine  
Saint Louis, Missouri



**Joshua W. Knowles, MD, PhD**

Assistant Professor, Cardiovascular Medicine  
Stanford University  
Attending Physician, Stanford Center for  
Inherited Cardiovascular Disease  
Director, Familial  
Hypercholesterolemia (FH) Clinic  
Program Director, Stanford Cardiovascular  
Medicine Fellowship Program  
Co-director, Stanford Translational  
Investigator Program  
Stanford, California



**Mikhail N. Kosiborod MD**  
**FACC, FAHA**

Professor of Medicine  
Saint Luke's Mid America Heart Institute  
University of Missouri-Kansas City  
School of Medicine  
Kansas City, Missouri



**Ronald M. Krauss, MD**

Senior Scientist and Director  
Atherosclerosis Research  
Children's Hospital Oakland Research Institute  
Adjunct Professor  
Department of Medicine, UCSF  
Adjunct Professor  
Department of Nutritional Sciences  
University of California, Berkeley  
Berkeley, California



**Rohit Kulkarni, MD, PhD**

Islet Cell and Regenerative Biology  
Co-Section Head and Senior Investigator  
Joslin Diabetes Center, Department of Medicine  
Brigham and Women's Hospital  
Harvard Stem Cell Institute  
Harvard Medical School  
Boston, Massachusetts



**John Leahy, MD**

Professor Emeritus, Department of Medicine  
Division of Endocrinology  
Diabetes and Metabolism  
Colchester, Vermont



**Norman E. Lepor, MD**  
**FACC, FAHA, FSCAI**

Clinical Professor of Medicine Geffen/UCLA  
School of Medicine  
Smidt Cedars-Sinai Heart Institute  
Westside Medical Associates of Los Angeles  
Los Angeles, California



**Philip Levy, MD, MACE**

Clinical Professor of Medicine  
University of Arizona College of Medicine  
Endocrinologist  
Banner University Medical Group  
Phoenix, Arizona

# FACULTY 2021



**Ildiko Lingvay, MD MPH, MSCS**

Professor of Medicine  
Department of Internal Medicine  
Division of Endocrinology and  
Department of Population and Data Sciences  
Medical Director  
Office of Clinical Trial Management  
University of Texas  
Southwestern Medical Center  
Dallas, Texas



**Christos S. Mantzoros, MD DSc, PhD h.c. mult.**

Professor of Medicine  
Harvard Medical School and  
Boston University School of Medicine  
Chief of Endocrinology  
Diabetes and Metabolism  
Boston VA Healthcare System  
Director of Human Nutrition, Beth Israel  
Deaconess Medical Center  
Editor-in-Chief, Metabolism,  
Clinical & Experimental  
Boston, Massachusetts



**Tracey L. McLaughlin, MD, MS**

Professor of Medicine  
Division of Endocrinology  
Stanford University School of Medicine  
Stanford, California



**Christian W. Mende, MD FACP, FACN, FASN, FASH**

Clinical Professor of Medicine  
University of California San Diego  
La Jolla, California



**Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC**

Associate Professor of Medicine (Cardiology)  
and Epidemiology  
Associate Director of Preventive Cardiology  
Johns Hopkins University School of Medicine  
Baltimore, Maryland



**Andrew Moran, MD, MPH**

Director, Global Hypertension Control  
Resolve to Save Lives  
Associate Professor of Medicine  
Columbia University  
New York, New York



**Mazen Nouredin, MD**

Director, Cedars-Sinai Fatty Liver Program  
Los Angeles, California



**Richard E. Pratley, MD**

Samuel E. Crockett Chair in Diabetes Research  
Medical Director  
AdventHealth Diabetes Institute  
Senior Investigator and Diabetes Program Lead  
AdventHealth Translational Research Institute  
Adjunct Professor of Medicine  
Johns Hopkins University School of Medicine  
Orlando, Florida



**Peter Reaven, MD**

Professor of Clinical Medicine  
University of Arizona  
Phoenix, Arizona



**Paul D. Rosenbitt MD PhD, FACE, FNLA**

Clinical Professor, Medicine  
Division of Endocrinology  
Diabetes Metabolism  
University of California, Irvine (UCI)  
School of Medicine  
Co-Director, Diabetes Outpatient Clinic  
UCI Medical Center, Orange, CA  
Director, & Site Principal Investigator  
Diabetes / Lipid Management &  
Research Center  
Huntington Beach, California



**Julio Rosenstock, MD**

Director, Dallas Diabetes Research Center  
Medical City Dallas  
Clinical Professor of Medicine  
University of Texas Southwestern  
Medical Center  
Dallas, Texas



**Donna H. Ryan, MD**

Professor Emerita  
Pennington Biomedical Research Center  
New Orleans, Louisiana



**Philipp E. Scherer, PhD**

Touchstone Diabetes Center  
The University of Texas Southwestern  
Medical Center  
Dallas, Texas



**Gerald I. Shulman, MD, PhD**

George R. Cowgill Professor of Medicine  
(Endocrinology)  
Professor of Medicine and Cellular  
& Molecular Physiology  
Co-Director Yale Diabetes Research Center  
Yale University School of Medicine  
New Haven, Connecticut



**Alan R. Sinaiko, MD**

Professor, Department of Pediatrics  
Division of Pediatric Nephrology  
University of Minnesota Medical School  
Minneapolis, Minnesota



**Jay S. Skyler, MD, MACP**

Professor of Medicine  
Pediatrics and Psychology  
Deputy Director, Diabetes Research Institute  
University of Miami  
Miami, Florida



**Laurence Sperling, MD FACC, FAHA, FACP, FASPC**

Katz Professor in Preventive Cardiology  
Founder, Emory Heart Disease Prevention  
Professor of Global Health  
Emory University  
Atlanta, Georgia

## FACULTY 2021



**Pam R. Taub, MD, FACC, FASPC**

Director of Step Family Foundation  
Cardiovascular  
Rehabilitation and Wellness Center  
Professor of Medicine  
UC San Diego Health System  
Division of Cardiovascular Medicine  
La Jolla, California



**Guillermo Umpierrez, MD, CDE**

Professor of Medicine  
Division of Endocrinology, Metabolism, and  
Lipids  
Emory University  
Atlanta, Georgia



**Phil Zeitler, MD, PhD**

Medical Director, Children's Hospital Colorado  
Clinical & Translational Research Center,  
Section Head, Endocrinology  
Aurora, Colorado



**Robert D. Toto, MD**

Professor of Internal Medicine  
Associate Dean Translational Science  
and Education  
University of Texas Southwestern Medical  
Center  
Dallas, Texas



**Matthew R. Weir, MD**

Professor and Chief  
Division of Nephrology  
Department of Medicine  
University of Maryland School of Medicine  
Baltimore, Maryland

### 19TH WCIRDC PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Richard N. Bergman, PhD • Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD  
Sonia Caprio, MD • Robert J. Chilton, DO • Kenneth Cusi, MD • Jaime Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD  
Vivian A. Fonseca, MD • W. Timothy Garvey, MD • Peter J. Grant, MD • Jennifer Green, MD • George Grunberger, MD  
Chris K. Guerin, MD • Paul S. Jellinger, MD • Samuel Klein, MD • Mikhail N. Kosiborod, MD  
Ronald M. Krauss, MD • Norman Lopor. MD • Derek LeRoith, MD, PhD • Philip Levy, MD • Christos Mantzoros, MD, DSc  
Nikolaus Marx, MD • Tracey L. McLaughlin, MD • Christian W. Mende, MD • Jorge Plutzky, MD • Richard E. Pratley, MD  
Arun J. Sanyal, MD • Philipp E. Scherer, PhD • Bart Staels, PhD • Pam R. Taub, MD • Muthiah Vaduganathan, MD, MPH  
Matthew R. Weir, MD • Paul Zimmet, AO, PhD • Renee S. Asp, BS

### ACCOMMODATIONS

The 19th Annual World Congress on Insulin Resistance, Diabetes & CVD (WCIRDC) will be held at the prestigious Hilton Universal City Hotel. The majestic Hilton Hotel is situated on a high hill above the Los Angeles entertainment district, near Universal Studios Hollywood and City Walk. The hotel is located a block from the main entrance of Universal Studios Hollywood, and is also a 3.5-mile drive to Pantages Theatre for Broadway shows. This 24-story hotel offers upscale rooms with panoramic views of the Hollywood Hills and Universal Studios.

Hilton Universal City Hotel 555 Universal Hollywood Drive Universal City, CA 91608

To reserve a room at our special rate of \$216 a night for conference participants and their guests visit <https://www.wcir.org/accommodations>

Guests can also call In-House Reservations Dept. at 818-623-1434 from 8:30am-5pm PST Please reference the group name: WCIRDC

# REGISTRATION INFORMATION

[www.WCIR.ORG/registration](http://www.WCIR.ORG/registration)

Email: [info@tmioa.com](mailto:info@tmioa.com) | To register by phone: 818-342-1889

All 19th WCIRDC participants must be vaccinated in order to attend the live in person meeting. For further information please contact [info@tmioa.com](mailto:info@tmioa.com)

**Cancellation Policy:** A full refund will be given if written notice of cancellation is received by September 6, 2021. A \$75 cancellation fee will be charged for cancellation between September 7, 2021 and November 2, 2021. After November 2, 2021 there will be NO REFUNDS - only registration transfer credit will be offered. Cancellations must be submitted via e-mail to [info@tmioa.com](mailto:info@tmioa.com) or by phone at 818-342-1889.

## CME ACCREDITATION

For CME questions related to WCIRDC, please contact our CME Coordinator Renee Asp at [renee@aspencmehelp.com](mailto:renee@aspencmehelp.com). This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

## AMA PRA DESIGNATION STATEMENT

PESI Inc. has designated this Other (Live and Internet Live ) activity for a maximum of 24 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## MOC POINTS WITH ABIM

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC points 24.

## INTERNATIONAL CME

International Physicians are formally eligible for AMA PRA Category 1 Credit<sup>™</sup>.

## PHYSICIAN ASSISTANTS

AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit<sup>™</sup> for the PRA from organizations accredited by ACCME.

## NURSES

For the purpose of re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit<sup>™</sup> issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

## CA NURSES

Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 19th WCIRDC for a total of 24 contact hours.

## PHARMACISTS

For the purpose of re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit<sup>™</sup> issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

## CDE

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. Total qualifying continuing education hours 24.

## REGISTERED DIETITIANS

For the purpose of re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit<sup>™</sup>.

## SATISFACTORY COMPLETION FOR CREDITS

All attendees must have completed and submitted an online course attendance/evaluation immediately following onsite or virtually live attendance. Each session claimed for credit must be attended in its entirety. Attendees will be able to print a certificate of attendance following the submission of online evaluation. Physician certificates of credit will be emailed two to three weeks after the CME activity.

## ENDURING/ ON-DEMAND CME ACTIVITY

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

## AMA PRA DESIGNATION STATEMENT

PESI Inc. has designated this Enduring activity for a maximum of 24 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available online at [www.wcirdc.com](http://www.wcirdc.com) from December 6, 2021 through March 4, 2022.

## **ASSOCIATED ORGANIZATIONS**

### **Premier Associated Organizations**

- California Chapter of the American College of Cardiology (CAACC)
- Clinical Association of California Endocrinologists (CACE)
- Cardio Renal Society of America (CRSA)

### **Associated Organizations**

- American Society of Endocrine Physician Assistants (ASEPA)
- Association of Diabetes Care & Education Specialists (ADCES)
- Endocrine Nurses Society (ENS)
- International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
- Israel Endocrine Society (IES)
- Italian Society of Endocrinology (SIE)
- Point of Care Network (POCN)
- World Obesity Federation

## **MEDIA PARTNERS**

### **Premier Media Partners**

- Metabolism (Elsevier)
- American Journal of Cardiology (Elsevier)
- American Journal of Managed Care (MJH Life Sciences)
- Endocrinology Network (MJH Life Sciences)
- HCPLive Network (MJH Life Sciences)
- Healio: Cardiology Today & Endocrine Today
- Practical Cardiology (MJH Life Sciences)
- The Lancet Diabetes & Endocrinology

### **Media Partners**

- Cardiovascular Endocrinology & Metabolism (Wolters Kluwer)
- ConferenceLocate.com
- Diabetes & Vascular Disease Research (Sage)
- Diabetes in Control
- Endocrine Web
- Frontiers in Clinical Diabetes and Healthcare
- Healthcare Tech Outlook
- Journal of Diabetes
- MEDtube
- Nutrients
- PharmaVoice
- Physician's Weekly
- Vessel Plus

## **FOR ADDITIONAL INFORMATION ON**

Registration | Support | Exhibits

(818) 342-1889 | [info@tmioa.com](mailto:info@tmioa.com) | [www.WCIR.ORG](http://www.WCIR.ORG)





**THE INTERNATIONAL COMMITTEE FOR  
INSULIN RESISTANCE GRATEFULLY ACKNOWLEDGES**

**CORPORATE SUPPORT**

**EMERALD LEVEL**

**ESPERION®**

**AsahiKASEI**

 **Abbott**

 **Corcept**  
THERAPEUTICS

 **Boehringer  
Ingelheim** *Lilly*

 **FRACTYL®**  
health

**TOPAZ LEVEL**

 **APPLIED  
THERAPEUTICS**

**UNRESTRICTED EDUCATIONAL GRANT**

**BAYER**

**ASTRAZENECA**

**PFIZER / MERCK ALLIANCE**

**ZEALAND PHARMA**

**NOVO NORDISK**

**AMARIN PHARMA**